Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of...

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Elevated plasma TGF-beta 1 was observed post-chemotherapy in advanced breast cancer patients.
• It was unclear if TGF-beta 1 elevation resulted from chemotherapy or the tumor itself.

Purpose of the Study:

• To determine if untreated breast cancer patients exhibit elevated plasma TGF-beta 1 levels.
• To investigate the correlation between TGF-beta 1 levels and tumor status.

Main Methods:

• Plasma TGF-beta 1 levels were measured using ELISA in 26 newly diagnosed breast cancer patients pre- and post-surgery.
• Patients were categorized by lymph node status and residual disease.
• Immunohistochemistry and in situ hybridization localized TGF-beta 1 production.

Main Results:

• 81% of patients had elevated preoperative plasma TGF-beta 1; TGF-beta 2 and 3 were undetectable.
• Preoperative TGF-beta 1 levels were similar across patient groups.
• Postoperative levels normalized in patients without lymph node metastases but remained elevated in those with positive nodes or residual disease.
• TGF-beta 1 expression was primarily increased in tumor stroma.

Conclusions:

• Breast tumors are associated with increased plasma TGF-beta 1 in most patients.
• Plasma TGF-beta 1 normalization post-surgery suggests tumor dependence.
• Persistently high TGF-beta 1 levels correlate with lymph node metastasis or residual disease.
• TGF-beta 1 warrants further investigation as a potential plasma biomarker for breast cancer.